The once-daily human GLP-1 analogue liraglutide decreases postprandial hunger and energy intake

被引：0
|
作者：
Flint, Anne
Kapitza, Christoph
Hinds-Berger, Charlotte
Zdravkovic, Milan
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 50 条
  • [41] Liraglutide, a Once-Daily Human GLP-1 Analog, Lowers Systolic Blood Pressure (SBP) Independently of Concomitant Antihypertensive Treatment
    Fonseca, Vivian
    Plutzky, Jorge
    Montanya, Eduard
    Colagiuri, Stephen
    Hansen, Charlotte
    Falahati, Ali
    Devries, J. Hans
    DIABETES, 2010, 59 : A79 - A79
  • [42] Liraglutide, a Once-Daily Human GLP-1 Analog, Is Equally Effective and Tolerated Independent of Administration Time (Morning vs Evening)
    Kaku, Kohei
    Rasmussen, Mads
    Katayama, Yasuyuki
    Seino, Yutaka
    DIABETES, 2009, 58 : A144 - A144
  • [43] Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    A Astrup
    R Carraro
    N Finer
    A Harper
    M Kunesova
    M E J Lean
    L Niskanen
    M F Rasmussen
    A Rissanen
    S Rössner
    M J Savolainen
    L Van Gaal
    International Journal of Obesity, 2013, 37 : 322 - 322
  • [44] The once-daily human GLP-1 analog-liraglutide reduces systolic blood pressure in patients with type 2 diabetes
    Colagiuri, Steven
    Frid, Anders
    Zdravkovic, Milan
    Le-Thi, Tu Duyen
    Vaag, Allan
    DIABETES, 2008, 57 : A164 - A165
  • [45] The once-daily human GLP-1 analogue liraglutide preserves pancreatic beta cells in diabetic db/db mice through both acute and chronic action mechanisms
    Shimoda, M.
    Kanda, Y.
    Tawaramoto, K.
    Hashiramoto, M.
    Matsuki, M.
    Kaku, K.
    DIABETOLOGIA, 2008, 51 : S210 - S210
  • [46] The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials
    Plutzky, J.
    Garber, A. J.
    Falahati, A.
    Toft, A. D.
    Poulter, N. R.
    EUROPEAN HEART JOURNAL, 2009, 30 : 917 - 917
  • [47] Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes
    Plutzky, J.
    Garber, A.
    Toft, A. D.
    Poulter, N. R.
    DIABETOLOGIA, 2009, 52 : S299 - S300
  • [48] Treatment satisfaction in patients with type 2 diabetes is significantly improved with liraglutide, the once-daily GLP-1 analogue versus sitagliptin, both combined with metformin
    Montanya Mias, E.
    Cuddihy, R.
    Pratley, R.
    Hammer, M.
    Thomsen, A.
    Davies, M. J.
    DIABETOLOGIA, 2010, 53
  • [49] Once-Daily Human GLP-1 Analog Liraglutide Reduces Systolic BP-A Meta-Analysis of 6 Clinical Trials
    Fonseca, Vivian
    Madsbad, Sten
    Falahati, Ali
    Zychma, Marcin J.
    Plutzky, Jorge
    DIABETES, 2009, 58 : A146 - A146
  • [50] Tritium labelling of the GLP-1 analogue liraglutide
    Larsen, Uffe S.
    Hansen, Heidi B.
    Dahl, Anne-Metre
    Sorensen, Lone
    Kristensen, Jesper B.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2007, 50 (5-6): : 549 - 550
12345